Similarly to GAGs, i.e., the first, upward trend was observed until the 6th month of treatment (T6), whereas the continuation of ETA therapy in patients with JIA led to a gradual decrease in plasma concentrations of circulating MMP-1 and MMP-3. The gene discussed is MMP3; the disease is juvenile idiopathic arthritis.